JR-141
Asset
Recombinant iduronate-2-sulfatase enzyme replacement therapy engineered to penetrate the blood-brain barrier.
- Stage
- Human trials
- Modality
- Protein or enzyme
- Target
- Proteostasis
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Hunter syndrome
Human trials, businesswire.com, 2 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners3
- Evidence for its targets1
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.